Home Patent Forecast® Sectors Log In   Contact  
How it works Patent Forecast® Sectors Insights
Menu

GM bringing motion sickness management into cars

AI Biotech/Diagnostics: Other Innovation Patent Forecast®

June 20, 2019

General Motors is well known for their prowess in the automotive industry, and much of their success is due to an extensive patent portfolio. All told, the company has over 13,000 issued patents – but of course many of those relate to automobile parts such as the engine. Until now. In the last three months, GM has been issued two patents regarding motion sickness in the car; specifically, GM is using sensors and AI to detect that an individual has motion sickness and then to respond to that by doing things such as altering cabin conditions. With the rise of driverless vehicles,  this technology could become increasingly important as the driver is more likely to experience confusion between motions inside and outside of the car when not actively steering. It is worth noting that Jaguar and Volkswagen are also working on ways to mitigate motion sickness, but they have not appeared in the AI Biotech sector yet.


Relevant Patent Documents

Patent US10259451  

Patent US10322259  

Article Source Link

Forbes


View Patent Forecast®

Artificial intelligence and human health don’t stop with our general diagnostics, cardiology, neurology, and activity sectors. This sector covers AI/ML-centric advancements in auditory, dental, GI/hepatic, circulatory, immune, musculoskeletal, ocular, reproductive, respiratory, dermatological, urinary, rectal, and spectrometry related biotech.

AI Biotech/Diagnostics: Other Innovation   Patent Forecast®

View Patent Forecast® Top Corporations News and Insights Data Visualization

Artificial intelligence and human health don’t stop with our general diagnostics, cardiology, neurology, and activity sectors. This sector covers AI/ML-centric advancements in auditory, dental, GI/hepatic, circulatory, immune, musculoskeletal, ocular, reproductive, respiratory, dermatological, urinary, rectal, and spectrometry related biotech.



301